BridgeMD
New treatment option for Rosacea
Official title Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
ClinicalTrials.gov ID: NCT06072066
What this study is testing
- What it's testing
- The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 70. Healthy volunteers may be eligible.
You may be able to join if
- Males and females 30 to 70 years of age
- The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
- High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L
You likely can't join if
- The presence of severe rosacea as noted by the investigator global assessment.
- Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
- Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
- Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.
- Those who are unwilling to keep their facial regimen the same throughout the study.
- Individuals who have been on an oral antibiotic within the previous one month.
See the full eligibility criteria
- Males and females 30 to 70 years of age
- The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
- High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L
- The presence of severe rosacea as noted by the investigator global assessment.
- Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
- Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
- Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.
- Those who are unwilling to keep their facial regimen the same throughout the study.
- Individuals who have been on an oral antibiotic within the previous one month.
- Individuals who are pregnant or breastfeeding.
- Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.
- Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.
- Use of isotretinoin within the three months prior to enrollment.
- Individuals on finasteride or dutasteride
- Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.
The study team makes the final eligibility decision.
Where it's taking place
- Sacramento, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 70 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sacramento, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.